Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer | Zendy

Kono Koji | Zendy; Takahashi Akihiro | Zendy; Amemiya Hideki | Zendy; Ichihara Fumiko | Zendy; Sugai Hidemitsu | Zendy; Iizuka Hidehiko | Zendy; Fujii Hideki | Zendy; Matsumoto Yoshiro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

Author(s) -

Kono Koji,

Takahashi Akihiro,

Amemiya Hideki,

Ichihara Fumiko,

Sugai Hidemitsu,

Iizuka Hidehiko,

Fujii Hideki,

Matsumoto Yoshiro

Publication year - 2001

Publication title -

international journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.475

H-Index - 234

eISSN - 1097-0215

pISSN - 0020-7136

DOI - 10.1002/ijc.10179

Subject(s) - cancer , immunotherapy , immunohistochemistry , human leukocyte antigen , medicine , tumor infiltrating lymphocytes , antigen , population , cytotoxic t cell , cancer research , immunology , pathology , biology , biochemistry , environmental health , in vitro

We have identified that HER‐2/neu‐derived peptides are naturally processed as tumor rejection antigens recognized by tumor‐specific, HLA‐A2‐restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER‐2/neu‐derived, HLA‐A2‐restricted peptides, we examined the frequency of HLA‐A2 relating to HER‐2/neu overexpression or the infiltrating grade of tumor‐infiltrating lymphocytes (TILs) in Japanese patients with gastric cancer. HER‐2/neu‐overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA‐A2‐positive patients with gastric cancer were 31% of primary gastric‐cancer cases. Finally, gastric‐cancer patients with both HLA‐A2‐positive and HER‐2/neu‐overexpressing tumors amounted to 6.6% of these cases. There was no significant difference in the infiltrating grade of TILs between gastric cancers overexpressing HER‐2/neu and those that did not. The candidate for HER‐2/neu‐based immunotherapy with HLA‐A2‐restricted peptides represent a very limited population of Japanese patients. © 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research